CULLINAN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.81 USD | -10.89% |
|
-12.37% | +133.66% |
Presenter SpeechUnknown Analyst (Analysts)Great. Thanks, everyone, for joining us this afterno...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.
Calendar
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
23.81
USD
Average target price
33
USD
Spread / Average Target
+38.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +133.66% | 1.15B | |
| +33.37% | 49.46B | |
| +1.55% | 42.58B | |
| +49.11% | 42.49B | |
| -4.22% | 29.09B | |
| +11.57% | 26.61B | |
| -21.00% | 18.64B | |
| +7.36% | 13.16B | |
| +28.30% | 12.55B | |
| +23.80% | 12.1B |
- Stock Market
- Equities
- CGEM Stock
- News Cullinan Therapeutics, Inc.
- Transcript : Cullinan Oncology, Inc. Presents at Barclays Global Healthcare Conference 2022, Mar-16-2022 03
